Just posting some old info to show we are close, imminent as...

Just posting some old info to show we are close, imminent as they say just a little slow. Expected sales end of April/May so must be close.

20 December, 2007 Company Announcement Expanding Production Facilities in Tomsk The Directors of Solagran Limited are pleased to announce the achievement of two important milestones in the ongoing development of its Bioeffective® R production facilities in Tomsk. Increase in Shareholding in SibEX In anticipation of production commencing at the Tomsk A production facility in January 2008, Solagran has now increased its holding in SibEX from 60 percent to 85 percent. The Tomsk A production facility will have the capacity to produce 20kg per month of Bioeffective R. It should be operating at full capacity by March 2008. Securing Site for Tomsk B Production Facility Solagran will today submit an application that will secure its chosen site in the Tomsk special economic zone. The enclosed letter provides further information in relation to the application process. The Tomsk B facility will have the potential to manufacture 200kg per month of Bioeffective R. This capacity will be required within 18 months to meet demand in Russia. This facility will also provide a template for roll out to build Solagran's manufacturing footprint in Western Europe and the Pacific Northwest. The Directors will present further information in relation to both these matters at the AGM this Friday. Peter Stedwell Company Secretary On behalf of the Board of Directors of Solagran Limited Attachments 1. Letter from ….. RusSEZ TERRITORIAL AUTHORITY OF FEDRAL AGENCY FOR THE COUNCIL OF SPECIAL ECONOMIC ZONES To the CEO of the company Solagran Limited Dr Soultanov FOR TOMSK OBLAST (TA RusSEZ for Tomsk Oblast) DEPUTY DIRECTOR 148Krasnoarmeiskaya street, Tomsk city, 634034 Telephone: (3833) 42-20-06, Fax: (3822) 42-19-32 Email: Office@tomskoez. ru Dated 18/12/2007 No 01-06/550 About the completion of the project of LLC"Sibex" in SEZ of Tomsk city Dear Vagif Soultanovich, Taking into consideration the interest of your company in completion of the biotechnology project in the territory of the special economic zone in the city of Tomsk, The Territorial Authorityof Federal Agency for the Council of Special Economic Zones in the Tomsk Oblast (TA RusSEZ) informs you about the fact that the building of the infrastructure and the appropriation of the land plots for building objects for residents in accordance with the planning concept of development of the Special Economic Zone of the city of Tomsk is continuing. Currently, we are up taking the first stage, which covers the creation of 30% of business, engineering and transport infrastructure by 2009. The second stageis planned for completion in 2009-2011. Taking this into account, for the rational planning and effective provision of plots for construction, we propose to the companies interested in construction of own building sites in 2008-2009 to lodge an application for making of an agreement for conducting technical implementation activity in the SEZ of Tomsk into the TA RusSEZ before the 15th of February 2008. Please be informed, that the next scheduled review of documents of applicants in the Expert Council of RusSEZ is set for 20th February 2008. The application form for establishment of resident status was sent to the address of LLC "Sibex" on the 18th of December of 2007. We will be very grateful to you, Vagif Soultanovich, for the earliest resolution of this question about the terms of completion of the project and lodgment of the application to TA RusSEZ. With hope for your understanding and cooperation. DeputyManager V.I. Podatkov Kuznetsova L.G (3822) 421934

28February 2008 Company Announcement Receipt of Manufacturing Licence for Ropren® Further to Solagran'sASX announcement of 20 February 2008 in which it was stated that the award of Manufacturing Licences for both the prescription pharmaceutical Ropren® and its active ingredient Bioeffective® R was imminent, the Directors of Solagran are pleased to announce that the Ministry of Health of the Russian Federation has now issued these licences. The Directors believe that based on the attached letterfrom the General Director of Galenopharm (Solagran's manufacturing partner in St Petersburg), Ropren® will be available for sale in Russia towards the end of April 2008 after it is officially released. This is now just an administrative formality. In the meantime, the company will officially advise the hospital networks in Moscow and St Petersburg of Ropren's impending availability. As was announced on 18 July 2007 when Ropren® was approved as a pharmaceutical and entered into the Russian Pharmacopoeia, supply constraints mean that distribution will initially be limited to Moscow andSt Petersburg. The company is currently working on a number of initiatives to put in place manufacturing capacity sufficient to meet the expected demand from both the remainder of Russia and the CIS countries. The Directors would like to congratulate all members of the team involved in what has been a long and complex regulatory approval process. Special thanks are due to Mr Tamerlan Aslanbekovich Balaev of Galenopharm, for his tireless efforts throughout the entire regulatory approval process. Peter Stedwell Company Secretary On behalf of the Board of Directors of Solagran Limited St-Petersburg Pharmaceutical Factory Ltd 27 February 2008 No.4-240-262 V.S. Soultanov Chairman Solagran Limited Dear Vagif Soultanovich, We advise you that for sale of a therapeutic substance it is required 3 documents: -registration certificate -manufacturing license -official release to market The official release to market is issued by the Federal Authority for Supervision of Healthcare and Social Development of the Russian Health Inspectorate based on the letter [issued on 15 February and received last week] from the Institute for Standardisation and Control of Therapeutic Substances about release from preliminary control.1 This is controlled by the Department of State Control of Manufacturing of Therapeutic Substances of the State Authority for Control of Distribution of Medical Products and Products for Rehabilitation of Invalids of the Federal Service. The release to market will be received in 1-1.5 months. T. A Balayev General Director 1 Note. The Institute for Standardisation and Control of Therapeutic Substances is part of the Federal Authority "Scientific Centre for Examination of Substances for Medicinal Use"

Solagran granted approval for Ropren in Russia

Published: 20 Mar 2008

Solagran granted approval for Ropren in Russia
Solagran has reported that the Russian regulatory authorities were expected to release its new prescription pharmaceutical Ropren for sale in the Russian market within 30 to 45 days.

Solagran's manufacturing partner Galenopharm is now free to commence production of Ropren for sale throughout Russia. Solagran is hopeful that initial production volumes will be sufficient to meet the needs of the main population centres of Moscow and St Petersburg.

Solagran will now turn its attention to ensuring that it is in a position to respond effectively to the significant world wide interest in this product. A plant containing the world's first commercial polyprenols production facility is due to be opened shortly by the Governor of the Tomsk region. When operated at full capacity, this facility will generate sufficient polyprenols (Bioeffective R) to produce 50-60,000 courses of Ropren per annum.(now 120,000 courses per year)

These two events constitute a really major milestone for the company and mark the beginning of Solagran's transition from a research-focused biotechnology company into an important player in the international natural pharmaceuticals market.

Just bored and checking again why I have been buying and holding. Bye all.